Trial reportJournal of diabetes and its complications
Haptoglobin 2-2 genotype and the risk of coronary artery disease in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications study (DCCT/EDIC).
Trial report in Journal of diabetes and its complications. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.
- Association between haptoglobin polymorphism and coronary artery disease: a meta-analysis.Frontiers in genetics · 2024Pooled it
- Precision medicine approach to coronary artery disease: Haptoglobin phenotype‑guided risk assessment.Molecular medicine reports · 2026Article
- Second international consensus report on gaps and opportunities for the clinical translation of precision diabetes medicine.Nature medicine · 2023Review
- Cardiovascular Disease in Adults with Type 1 Diabetes: Looking Beyond Glycemic Control.Current cardiology reports · 2022Review
- Cardiovascular and Metabolic Protection by Vitamin E: A Matter of Treatment Strategy?Antioxidants (Basel, Switzerland) · 2020Review
- The haptoglobin 2-2 genotype is associated with cardiac autonomic neuropathy in type 1 diabetes: the RETRO HDLc study.Acta diabetologica · 2020Article
- Targeted genotyping for the prediction of celiac disease autoimmunity development in patients with type 1 diabetes and their family members.World journal of diabetes · 2019Article
- The early detection of atherosclerosis in type 1 diabetes: why, how and what to do about it.Cardiovascular endocrinology & metabolism · 2019Review
- Association between serum haptoglobin and carotid arterial functions: usefulness of a targeted metabolomics approach.Cardiovascular diabetology · 2019Article
- Meta-analysis of the association of the haptoglobin genotype with cardiovascular outcomes and the pharmacogenomic interactions with vitamin E supplementation.Pharmacogenomics and personalized medicine · 2018Article
- The Iron-Klotho-VDR Axis Is a Major Determinant of Proximal Convoluted Tubule Injury in Haptoglobin 2-2 Genotype Diabetic Nephropathy Patients and Mice.Journal of diabetes research · 2018Article
- Progress in Defining the Genetic Basis of Diabetic Complications.Current diabetes reports · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 2 countries.
Funding
Abstract
aims/hypothesisHaptoglobin(Hp) 2-2 genotype has been shown to increase coronary artery disease (CAD) risk in numerous type 2 diabetes studies but in only one type 1 diabetes cohort. We assessed the association of Hp2-2 with incident CAD over 26years of follow-up in 1303 Caucasian participants of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) study.
methodsDCCT randomized volunteers with type 1 diabetes to intensive versus conventional therapy within two cohorts: 'primary prevention' with 1-5years diabetes duration and 'secondary intervention' with 1-15years diabetes duration and early retinopathy, with or without albuminuria, but no advanced complications. CAD was defined as myocardial infarction (MI) or death judged to be from CAD, silent MI, angina, coronary revascularization, or congestive heart failure due to CAD.
resultsIn the entire DCCTcohort, Hp2-2 was not significantly associated with incident CAD or MI. However, in pre-specified exploratory subgroup analyses, an increased MI risk was suggested in the secondary cohort for those with Hp2-2. CONCLUSIONS/
interpretationThe analysis does not statistically confirm an overall association between Hp 2-2 and incident CAD, however, some suggestions of associations were observed in secondary analyses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.